568582-98-9

Basic information

• Product Name: THIENO[3,2-C]PYRIDIN-2-YL BORONIC ACID
• Synonyms: THIENO[3,2-C]PYRIDIN-2-YL BORONIC ACID
• CAS NO: 568582-98-9
• Molecular Formula: C7H6BNO2S
• Molecular Weight: 179
• Mol File: 568582-98-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 431.8±48.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 6.27±0.30(Predicted)
• CAS DataBase Reference: THIENO[3,2-C]PYRIDIN-2-YL BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: THIENO[3,2-C]PYRIDIN-2-YL BORONIC ACID(568582-98-9)
• EPA Substance Registry System: THIENO[3,2-C]PYRIDIN-2-YL BORONIC ACID(568582-98-9)

Safety Data

• Hazardous Substances Data: 568582-98-9(Hazardous Substances Data)

Upstream product

• 498-62-4 3-thiophene carboxaldehyde 
• 58754-96-4 N-(2,2-dimethoxyethyl)-4-methyl-N-3-(thienylmethyl)benzenesulfonamide 
• 58754-97-5 (2,2-dimethoxy-ethyl)-thiophen-3-ylmethyl-amine 
• 272-14-0 thieno[3,2-c]pyridine 
• 5419-55-6 Triisopropyl borate 

Relevant articles and documents

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

Rho-kinase inhibitors

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.